Steven Gannon - 07 Mar 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
07 Mar 2024
Net transactions value
-$601,615
Form type
4
Filing time
08 Mar 2024, 17:28:51 UTC
Previous filing
14 Jun 2023
Next filing
04 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Sale $46,450 -1,000 -6.7% $46.45 14,000 07 Mar 2024 Direct
transaction XENE Common Shares Sale $231,250 -5,000 -36% $46.25 9,000 07 Mar 2024 Direct
transaction XENE Common Shares Sale $231,512 -5,000 -56% $46.30 4,000 07 Mar 2024 Direct F1
transaction XENE Common Shares Sale $92,402 -2,000 -50% $46.20 2,000 07 Mar 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.3025 to $46.3675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.20 to $46.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.